Combination of pixantrone with rituximab, ifosfamide and etoposide in relapsed/refractory aggressive non‐Hodgkin lymphoma. Results from a phase II LYSA study (PIVeR).

MLA

Fornecker, L., et al. “Combination of Pixantrone with Rituximab, Ifosfamide and Etoposide in Relapsed/Refractory Aggressive Non‐Hodgkin Lymphoma. Results from a Phase II LYSA Study (PIVeR).” Hematological Oncology, vol. 41, June 2023, p. 437. EBSCOhost, https://doi.org/10.1002/hon.3164_322.

APA

Fornecker, L., Delwail, V., Thieblemont, C., Ghesquieres, H., Bouabdallah, K., Tilly, H., Le Calloch, R., Morschhauser, F., Costello, R., Slama, B., Gyan, E., Chauchet, A., Ngirabacu, M., Durot, E., Choquet, S., Capdupuy, C., Le Goff, M., Voillat, L., Snauwaert, S., & Amorim, S. (2023). Combination of pixantrone with rituximab, ifosfamide and etoposide in relapsed/refractory aggressive non‐Hodgkin lymphoma. Results from a phase II LYSA study (PIVeR). Hematological Oncology, 41, 437. https://doi.org/10.1002/hon.3164_322

Chicago

Fornecker, L., V. Delwail, C. Thieblemont, H. Ghesquieres, K. Bouabdallah, H. Tilly, R. Le Calloch, et al. 2023. “Combination of Pixantrone with Rituximab, Ifosfamide and Etoposide in Relapsed/Refractory Aggressive Non‐Hodgkin Lymphoma. Results from a Phase II LYSA Study (PIVeR).” Hematological Oncology 41 (June): 437. doi:10.1002/hon.3164_322.